ChemBriefNovo Says CagriSema Tops Eli Lilly Rival in Diabetes Patients for Weight Loss
Novo Nordisk announced its experimental drug CagriSema achieved 12.4% average weight loss in late-stage diabetes trials, outperforming Eli Lilly's tirzepatide at 9.1%. The combination therapy position
reuters · 2026-09-21 03:46